HBM Partners

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

1000Farmacie is a prominent pharmacy marketplace in Italy that operates an online shopping platform dedicated to providing a diverse selection of pharmaceutical products. By collaborating with a network of independent pharmacies, the company ensures that customers can purchase healthcare items at competitive prices. The platform offers the convenience of same-day delivery to specified locations, enabling users to save both time and money while accessing essential health products.

ConnectRN, Inc. operates an online platform that connects healthcare providers, such as hospitals and clinics, with qualified nurses seeking employment. Founded in 2014 and based in Newton, Massachusetts, the platform streamlines communication between nurse managers and nursing staff through a web dashboard and an alert system that notifies nurses of available shifts on their mobile devices. This tech-enabled network not only facilitates the filling of open positions in healthcare facilities but also fosters a supportive community for nurses, enhancing their access to job opportunities and professional support.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Genalyte, Inc. is a clinical and diagnostic life science company that specializes in rapid diagnostic testing solutions for healthcare providers and researchers. Founded in 2007 and based in San Diego, California, Genalyte has developed the Maverick platform, which utilizes silicon photonics technology to directly measure the binding of biomolecules, such as antibodies and proteins, to silicon photonic biosensors. This innovative approach allows for the quick detection of various health conditions, including autoimmune diseases, cancer biomarkers, and infectious agents. The company’s systems enable mobile laboratories to deliver real-time diagnostics in under thirty minutes, enhancing the quality of care while optimizing resource use within the healthcare system.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Odyssey Therapeutics is a biotechnology company focused on developing next-generation immunomodulators and oncology drugs. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, identifying promising targets while reducing the likelihood of failure during development. Odyssey Therapeutics is committed to advancing the field of drug discovery and expediting clinical development, ultimately contributing to the creation of more effective precision medicines for the healthcare industry.

Vascular Dynamics, Inc. is a privately-held medical technology company founded in 2008 and based in Irvine, California. The company specializes in developing catheter-delivered implants for the treatment of drug-resistant hypertension. Its primary product, MobiusHD, utilizes a minimally invasive procedure to enhance the body's natural baroreceptor response in the carotid sinus, promoting vasodilation, lowering heart rate, modulating kidney response, and ultimately reducing blood pressure. Vascular Dynamics aims to provide effective treatment options for patients at risk of severe health conditions associated with high blood pressure, such as heart disease, stroke, and kidney disease. The team at Vascular Dynamics has over 75 years of combined experience in medical device development and commercialization.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Numab is a biotechnology company focused on developing antibody-based therapeutics for severe diseases, including chronic inflammation and cancer. The company employs a plug-and-play platform that minimizes the randomness typically associated with the drug discovery process, allowing for the predictable creation of multispecific biotherapeutics. This platform facilitates the development of mono- or multispecific antibody fragment-based therapeutics with customized pharmacokinetic properties, enabling the healthcare sector to address multiple therapeutic targets simultaneously. Through its innovative approach, Numab aims to enhance the effectiveness of immunotherapies in treating complex medical conditions.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company’s lead product candidate for infectious diseases, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial for patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, Hookipa is advancing its candidates HB-201 and HB-202, which target human papillomavirus-positive cancers and are in preclinical studies. The company employs its innovative VaxWave and TheraT platforms to stimulate robust immune responses, generating high levels of antigen-specific killer T cells and antibodies, which are essential for effective treatment. Additionally, Hookipa has partnered with Gilead Sciences to develop therapies aimed at achieving functional cures for chronic hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma is dedicated to transforming the landscape of immune therapies.

ConnectRN, Inc. operates an online platform that connects healthcare providers, such as hospitals and clinics, with qualified nurses seeking employment. Founded in 2014 and based in Newton, Massachusetts, the platform streamlines communication between nurse managers and nursing staff through a web dashboard and an alert system that notifies nurses of available shifts on their mobile devices. This tech-enabled network not only facilitates the filling of open positions in healthcare facilities but also fosters a supportive community for nurses, enhancing their access to job opportunities and professional support.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

i-Optics is a medical device company based in 's-Gravenhage, the Netherlands, that specializes in developing innovative corneal diagnostic solutions for eye care professionals. Founded in 2013, the company offers advanced technologies such as the Cassini Corneal Shape Analyzer, which utilizes color LED technology to accurately measure corneal astigmatism, aiding in premium intraocular lens (IOL) planning. This system helps cataract surgeons enhance patient outcomes and reduce unexpected refractive results. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system that employs scanning laser ophthalmoscopy (SLO) to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Through its user-friendly and cost-effective solutions, i-Optics aims to support eye care providers in delivering high-quality care to their patients.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Odyssey Thera, Inc., a biopharmaceutical company, develops cellular pharmacology strategy for the identification of medicines for human diseases. It focuses on the identification and development of treatment therapies for cancer. The company was formerly known as Odyssey Pharmaceuticals. Odyssey Thera, Inc. is based in San Ramon, California.

Reha Technology AG, headquartered in Olten, Switzerland, specializes in the design, manufacture, and global distribution of robotic-assisted systems aimed at neurorehabilitation. Founded in 2012, the company’s flagship product, the G-EO System, focuses on gait rehabilitation and is designed to assist patients with neurological movement disorders. Reha Technology's devices enhance the quality of life for individuals recovering from injuries or disabilities by realistically simulating activities such as stair climbing and addressing various gait disorders. The company aims to support patients in regaining the functional abilities necessary for independence in daily life. With a robust distributor network and direct operations in the United States and India, Reha Technology is also exploring expansion opportunities in Latin America.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents for treating serious infections. Its lead product candidate, XENLETA, is a semi-synthetic pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia and is also being investigated for other indications, including acute bacterial skin infections and pediatric infections. Additionally, the company is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at complicated urinary tract infections. Nabriva has established an exclusive agreement with Merck & Co. to market and distribute SIVEXTRO, an antibiotic for treating acute bacterial skin and skin structure infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics is dedicated to advancing its pipeline of anti-infective therapies.

Gemin X Pharmaceuticals focuses on the discovery, development, and commercialization of innovative cancer therapeutics aimed at enhancing patient outcomes. The company's research has centered on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070 (obatoclax), a small molecule designed to selectively trigger programmed cell death, or apoptosis, and potentially induce cancer cell autophagy. Obatoclax has demonstrated promising results in preclinical and early clinical trials and is currently undergoing Phase 2 clinical trials as both a standalone treatment and in combination with other therapies. Additionally, Gemin X is involved in developing other oncology products, including GMX1777, which inhibits NAD+ synthesis. The patent for obatoclax is secured until 2025, reinforcing the company's commitment to advancing cancer treatment options.

Asthmatx, Inc. is a medical device company based in Mountain View, California, that specializes in the development and commercialization of therapeutic treatments for asthma. Founded in 2003, the company has created a technology that delivers controlled thermal energy to the airways of adult patients, aimed at reducing the mass of airway smooth muscle through a procedure known as Bronchial Thermoplasty. Asthmatx offers the Alair System, an interventional medical device designed for bronchoscopic treatment of patients suffering from moderate to severe asthma. As of October 2010, Asthmatx operates as a wholly-owned subsidiary of Boston Scientific.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.

Anadys Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections. The company focuses on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 or TLR7. Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. As of November 22, 2011, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.

Aspreva Pharmaceuticals Corp, based in Victoria, British Columbia, is a pharmaceutical company dedicated to identifying and developing new indications for existing drugs aimed at underserved patient populations. The company employs a strategy known as "indication partnering," collaborating with other pharmaceutical and biopharmaceutical firms to explore new therapeutic approvals that align with its expertise. Aspreva focuses on complex diseases and specialized patient groups, utilizing a proprietary screening program to identify late-stage and approved medications that may offer significant therapeutic benefits for uncommon conditions. Through partnerships, Aspreva acquires rights to develop these drugs, encompassing clinical research, regulatory approvals, and specialized commercialization efforts tailored to these intricate therapeutic areas.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. The company is advancing several oncology programs, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently in Phase I trials for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia. CYC140, a polo-like kinase inhibitor, is also in Phase I trials for advanced leukemias. Additionally, sapacitabine, an oral nucleoside analogue prodrug, is being evaluated in a Phase 1/2 combination study with seliciclib, another CDK inhibitor, for patients with BRCA mutations. Cyclacel's pipeline includes collaborations with notable institutions, such as the University of Texas MD Anderson Cancer Center, to assess the safety and efficacy of its treatments in hematological malignancies. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Sloning BioTechnology specializes in the synthesis of DNA molecules through its innovative and patented Slonomics technology platform. This platform enables the production of DNA with unique features, including enhanced sequence limitations, reliability, and cost-effectiveness, all achieved on an industrial scale using automated robotic systems. In addition to gene synthesis, Sloning BioTechnology offers a range of synthetic biology tools, positioning itself as a key player in the field of biotechnology.

Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Syrrx Inc focuses on drug targets that have been validated in human clinical trials and directs its efforts toward therapeutics to treat metabolic diseases, cancer, and inflammation. Syrrx exploits its competitive advantage in high-throughput structural biology to be the first organization to determine the three dimensional structure of known drug targets. Syrrx then uses these structures to drive iterative, structure-based drug design programs to efficiently generate potential drug candidates. Syrrx has an ongoing partnership for the development and commercialization of Syrrx-designed human dipeptidyl peptidase IV (DPP IV) inhibitors as drug products for the treatment of type 2 diabetes and other major human diseases. Syrrx also has a strategic alliance for the discovery and early development of inhibitors targeting human HDACs and HSD1.